AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN), a pharmaceutical giant with a market capitalization of $215.44 billion and impressive gross profit margins of 82.61%, has received a recommendation for ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results from the ADRIATIC trial, in which patients were treated with Imfinzi for ...